Objective: We conducted a prospective cohort study to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval debulking surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for advanced-stage ovarian cancer Methods: In a single-center, we included 138 patients who had high tumor burden (Fagottis score>8 at diagnostic laparoscopy) and acheived complete remission or partial remission after three cycles of platinum-based chemotherapy to undergo interval debulking surgery either with or without administration of HIPEC. HIPEC was performed with paclitaxel (175m/m2) or cisplatin (100mg/m2) for 90 minutes according to surgeon’s discretion. The primary endpoint was progression-free survival. Overall survival and surgical outcome were key secondary endpoints. Results: From Oct 2015 to Dec 2018, 37 (26.8%) underwent interval debulking surgery followed by HIPEC (surgery plus HIPEC group) and 101 (73.2%) did interval debulking surgery without HIPEC (surgery group). There was no difference in grade III/IV perioperative complication between two groups. Surgery plus HIPEC group had longer operation time (543.8 munitues, range 277-915 minutes) and no cases of mortality were reported within 30 days postoperatively. In terms of survival, the median PFS and OS were not reached. Conclusion: Among patients with advanced-stage ovarian cancer, the addition of HIPEC to interval debulking surgery did not affect adverse surgical outcomes. Further evaluation of this procedure are required to assess its survival benefits.